Intensity Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INTS research report →
Range $7 – $15
Price Chart
About the company
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials.
- CEO
- Lewis H. Bender
- IPO
- 2023
- Employees
- 16
- HQ
- Shelton, CT, US
Get TickerSpark's AI analysis on INTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.70M
- P/E
- -0.57
- Fwd P/E
- 0.77
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.06
- EV/EBITDA
- 0.14
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -124.34%
- ROIC
- -159.88%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-26,000+0.0%
- Op Income
- $-11,972,000
- Net Income
- $-11,606,000+28.7%
- EPS
- $-8.56+70.7%
- OCF Growth
- +39.3%
- FCF Growth
- +39.3%
- 52W High
- $15.00
- 52W Low
- $2.28
- 50D MA
- $3.39
- 200D MA
- $4.73
- Beta
- 3.04
- RSI (14)
- 29
- Avg Volume
- 22.48K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Intensity Therapeutics reported a wider third-quarter loss as it restarted enrollment in both lead studies, advanced a new manufacturing batch, and said capital availability remains the main constraint on speed.· November 5, 2026
- Q3 R&D rose to $2.4 million from $1.6 million a year ago, driven by resumed trial activity, manufacturing, and employee-related costs.
- Net loss was $3.5 million versus $2.7 million in Q3 2025; G&A was flat at $1.3 million.
- The company restarted new patient enrollment in INVINCIBLE-3 at a limited number of U.S. sites and resumed enrollment in INVINCIBLE-4.
- Management said the INVINCIBLE-4 data presented at ESMO showed an early signal of benefit, including 71% pCR vs. 42% for standard of care in very small numbers.
- Cash was $8.5 million at September 30, 2026, with management planning to use the ATM and other financing sources opportunistically.
For the third quarter of 2026, Intensity Therapeutics reported research and development expense of $2.4 million versus $1.6 million in the prior-year quarter, an increase of $876,000 or 56%. General and administrative expense was $1.3 million, unchanged year over year. Net loss was $3.5 million compared with $2.7 million in Q3 2025, an increase of $873,000 or 33%. Cash and cash equivalents were $8.5 million at September 30, 2026. Operating cash burn for the nine months ended September 30, 2026 was $6.7 million, and the company expects operating cash burn to average about $1 million per month in Q4 2026. On guidance, management said INVINCIBLE-3 enrollment will expand in a gated way as capital is raised, INVINCIBLE-4 enrollment is targeted to complete by the end of 2027, and the phase II study is currently planned to run in France and Switzerland rather than U.S. sites.
Lewis Bender emphasized that the company made operational progress across both clinical programs, but repeatedly framed capital as the limiting factor on how quickly it can move. He highlighted the INVINCIBLE-3 protocol changes, including central review and Choi density criteria, saying the change was recommended by sarcoma experts to better assess progression for an intratumoral therapy. For INVINCIBLE-4, he pointed to the ESMO data as encouraging and said the company is working to reassure investigators on the revised dosing regimen and skin safety review.
Joseph Talamo said Q3 R&D increased because of resumed INVINCIBLE-3 activity, INVINCIBLE-4 trial costs, a new INT230-6 manufacturing batch, and higher compensation expense. He said INVINCIBLE-3 clinical trial expense was $1.5 million and INVINCIBLE-4 expense was $104,000 in the quarter, while the new manufacturing batch added $162,000 in costs. He noted cash and equivalents of $8.5 million, $1.5 million in ATM proceeds during Q3, and $3.2 million in ATM proceeds for the first nine months of 2026, and said the company will continue to use the ATM opportunistically while seeking both dilutive and non-dilutive capital.
Analysts focused on three issues: how the independent safety review for INVINCIBLE-4 would work, how many sites and patients could be activated in INVINCIBLE-3, and whether partnerships could reduce future cash needs. Management said the INVINCIBLE-4 review will mainly examine whether localized skin irritation persists over several months, while INVINCIBLE-3 enrollment is still pending patient screening and will be paced by available capital. On partnerships, Bender said the company is discussing both regional and multinational players, including potential licensing or co-development structures, but is still early in the process.
The company has restarted enrollment in both lead programs after prior pauses, which management portrayed as a meaningful operational step. Management also said the INVINCIBLE-4 ESMO data were encouraging, with 71% pCR versus 42% for standard of care in a very small cohort, and said investigators remain enthusiastic. In addition, Bender described active business-development interest from multiple large and regional companies, which could potentially bring in outside funding.
The biggest risk remains financing: management said capital will determine how quickly INVINCIBLE-3 and, to a lesser extent, INVINCIBLE-4 can advance. The quarter also showed continued losses and cash burn, with only $8.5 million in cash at quarter-end and expected Q4 operating burn of about $1 million per month. On the clinical side, INVINCIBLE-4 is still early, the safety review is ongoing, and management acknowledged the pCR data are based on very small numbers.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 53.9%
- Shares Outstanding
- 2.70M
- Float Shares
- 1.46M
of shares held by institutions
18 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 649.08K | ▲ 393.15K |
| Rothschild Wealth LLC | 29.22K | ▲ 2.50K |
| Vanguard Capital Management LLC | 26.57K | 0 |
| Nano Cap New Millennium Growth Fund L P | 25.00K | 0 |
| Geode Capital Management, LLC | 22.24K | ▼ 549 |
| Vanguard Fiduciary Trust Co | 21.07K | ▲ 11.95K |
| Mesirow Financial Investment Management, Inc. | 14.04K | ▼ 78 |
| State Street Corp | 10.65K | ▲ 10.65K |
| Cibc Private Wealth Group LLC | 5.03K | ▲ 25 |
| Newedge Advisors, LLC | 1.15K | 0 |
| Tower Research Capital LLC (Trc) | 1.00K | ▼ 980 |
| Citigroup Inc | 234 | ▲ 234 |
Held by 6 ETFs
Biggest fund positions in INTS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 16, 26 | DUBIN THOMAS I H | other | 5,500 |
| Jul 16, 26 | Donovan Daniel | other | 5,500 |
| Jul 16, 26 | GOLDBERG MARK A | other | 5,500 |
| Jul 16, 26 | Leahy Emer | other | 5,500 |
| Jul 16, 26 | Wesolowski John M | other | 11,000 |
| Jul 16, 26 | Talamo Joseph | other | 34,000 |
| Jul 16, 26 | BENDER LEWIS H | other | 78,000 |
| Jun 30, 26 | Wesolowski John M | other | 3,688 |
| Jun 30, 26 | Talamo Joseph | other | 1,093 |
| Mar 26, 26 | BENDER LEWIS H | other | 37,749 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INTS coverage
Recent articles, reports, and earnings notes.
No research on INTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INTS report →Intensity Therapeutics, Inc. (INTS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com · Nov 5
Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026
prnewswire.com · Oct 30
Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting
prnewswire.com · Oct 23
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com · Sep 8
Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 11
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
prnewswire.com · Aug 11
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
prnewswire.com · Aug 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.